Toll-like receptor 2 agonists inhibit human fibrocyte differentiation by Maharjan, Anu S et al.
RESEARCH Open Access
Toll-like receptor 2 agonists inhibit human
fibrocyte differentiation
Anu S Maharjan
1,2, Darrell Pilling
1,2, Richard H Gomer
1,2*
Abstract
Background: In healing wounds, some monocytes enter the wound and differentiate into fibroblast-like cells
called fibrocytes. Since Toll-like receptors (TLRs) are present on monocytes, and pathogens that can infect a wound
have and/or release TLR agonists, we examined whether TLR agonists affect fibrocyte differentiation.
Results: When human peripheral blood mononuclear cells (PBMCs) were cultured with TLR3, TLR4, TLR5, TLR7,
TLR8 or TLR9 agonists, there was no significant effect on fibrocyte differentiation, even though enhanced
extracellular tumor necrosis factor (TNF)-a accumulation and/or increased cell surface CD86 or major
histocompatibility complex (MHC) class II levels were observed. However, all TLR2 agonists tested inhibited
fibrocyte differentiation without any significant effect on cell survival. Adding TLR2 agonists to purified monocytes
had no effect on fibrocyte differentiation. However, some TLR2 agonists caused PBMCs to secrete a factor that
inhibits the differentiation of purified monocytes into fibrocytes. This factor is not interferon (IFN)-a, IFN-g,
interleukin (IL)-12, aggregated immunoglobulin G (IgG) or serum amyloid P (SAP), factors known to inhibit fibrocyte
differentiation. TLR2 agonist-treated PBMCs secrete low levels of IL-6, TNF-a, IFN-g, granulocyte colony-stimulating
factor and tumor growth factor b1, but combinations of these factors had no effect on fibrocyte differentiation
from purified monocytes.
Conclusions: Our results indicate that TLR2 agonists indirectly inhibit fibrocyte differentiation and that, for some
TLR2 agonists, this inhibition involves other cell types in the PBMC population secreting an unknown factor that
inhibits fibrocyte differentiation. Together, these data suggest that the presence of some bacterial signals can
inhibit fibrocyte differentiation and may thus slow wound closure.
Background
Following injury, circulating peripheral blood cells such
as neutrophils, monocytes, dendritic cells and lympho-
cytes leave the bloodstream and enter the injured site.
Once monocytes are in the injured site, they can differ-
entiate into fibroblast-like cells called fibrocytes [1-8].
Fibrocytes have a distinct spindle-shaped appearance.
Fibrocytes express hematopoietic markers, including
CD45, major histocompatibility complex (MHC) class II,
and CD34, along with stromal markers including col-
lagen I, collagen III, and fibronectin [1,9,10]. Fibrocytes
help to rebuild injured tissueb ys e c r e t i n ga n g i o g e n i c
and fibrogenic growth factors as well as matrix metallo-
proteinases [11]. Fibrocytes are also contractile cells,
which further helps to close wounds by pulling the
wound edges together [4].
We found that the serum protein serum amyloid P
(SAP) can directly inhibit monocytes from differentiat-
ing into fibrocytes [5]. Purified SAP inhibits fibrocyte
differentiation, but other serum proteins such as serum
amyloid A and C-reactive protein (CRP) are unable to
inhibit the differentiation of monocytes into fibrocytes
[5,12]. The profibrotic cytokines interleukin (IL)-4 and
IL-13 directly activate monocytes to differentiate into
fibrocytes, while cross-linked immunoglobulin G (IgG)
and the proinflammatory cytokine interferon (IFN)-g
directly inhibit the differentiation of monocytes into
fibrocytes [6,7]. Another proinflammatory cytokine, IL-
12, activates some cells in the peripheral blood mono-
nuclear cell (PBMC) population, possibly natural killer
(NK) cells, to indirectly inhibit fibrocyte differentiation
[7]. In human PBMC culture, IFN-a2b inhibits fibrocyte
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monocytes is unknown [13]. Other regulators of fibrocytes
include the adenosine A2A receptor and cysteinyl leuko-
triene receptor 1 (CysLT1) [14,15]. The adenosine A2A
receptor regulates cell proliferation and cytokine produc-
tion, and blocking this receptor inhibits the recruitment of
fibrocytes in bleomycin-treated mouse skin [14]. CysLT1
is a receptor for lipid mediators which promote fibroblast
proliferation, fibroblast chemotaxis and collagen synthesis
[15]. In mice with fluorescein isothiocyanate (FITC)-
induced lung fibrosis, blocking CysLT1 inhibits the
appearance of fibrocytes [15].
It is unclear why some of the above factors affect
fibrocyte differentiation. However, we hypothesized that
SAP prevents fibrocyte differentiation in the circulation
and that aggregated IgGs prevent fibrocyte differentia-
tion because aggregated IgGs signify the presence of
infection. We hypothesized that after monocytes detect
an infected wound, monocytes do not differentiate into
fibrocytes, since closing an infected wound could cause
further damage such as gangrene, an infectious wound
closure that results in further decay of the surrounding
cells [16,17]. The immune system can also recognize
pathogens using Toll-like receptors (TLRs) [18-24]. TLR
agonists include pathogen-specific molecules such as
lipopolysaccharides (LPSs) from gram-negative bacteria,
lipotechoic acid (LTA) from gram-positive bacteria, fla-
gellin from bacteria, single-stranded DNA (ssDNA) from
viruses and unmethylated DNA from bacteria [24,25].
TLR signaling pathways trigger innate immune
responses through nuclear factor (NF)-B-dependent
and IFN-regulatory factor-dependent pathways [19].
Since TLRs are present on monocytes, we examined
whether TLR agonists could also affect the differentia-
tion of monocytes into fibrocytes.
Methods
Culturing PBMC with TLR agonists or IFN-a
Blood was collected from healthy adult volunteers in
accordance with specific approval of Rice University’s
Institutional Review Board. Written consent was
received from all volunteers, and all samples were
deidentified before analysis. PBMCs were isolated and
incubated in serum-free media (SFM) as described pre-
viously [5-7,26]. TLR agonists (Invivogen, San Diego,
CA, USA) were reconstituted in endotoxin-free water
(Invivogen). All experiments were done with at least
three different batches of agonists. IFN-a was obtained
from EMD-Calbiochem (Darmstadt, Germany). A dilu-
tion series of TLR agonists (or the same volume of
water as a control) was made in serum-free medium. A
quantity of 100 μl of serum-free medium, TLR agonist
or IFN-a dilution, or water dilution, was added to dupli-
cate wells of a 96-well tissue culture plate (BD
Biosciences, San Jose, CA, USA). A quantity of 100 μlo f
human PBMCs at a concentration of 5 × 10
5 cells/ml in
serum-free medium was then added to each well. On
day 5, fields of PBMCs were photographed using a
phase-contrast microscope, and the number of cells per
image was counted. Cells were then fixed and stained,
and fibrocytes were counted as previously described
[5-7,26].
Preparation of monocytes
Monocytes were purified from 5 × 10
7 PBMCs using an
EasySep Monocyte Depletion Kit (catalog no. 19059;
StemCell Technology, Vancouver, BC, Canada) according
to the manufacturer’s instructions. To determine the pur-
ity of the monocytes, cells were analyzed using flow cyto-
metry (FACScan, BD Biosciences; or Accuri C6 cytometer,
Accuri Cytometers Inc., Ann Arbor, MI, USA) as
described previously [7]. A sample of each monocyte pre-
paration was stained with 5 μg/ml primary antibodies
against the T cell marker CD3, the monocyte marker
CD14, the NK cell marker CD16, the B cell marker CD19
and the leukocyte marker CD45 as previously described
[7]. Monocytes obtained were greater than 95% pure as
determined by the expression of CD14. Monocytes were
99% CD45-positive, 0.93% CD3-positive, 0.93% CD16-
positive and 1% CD19-positive. To assess the effect of
TLR2 agonists on monocytes, 5 μlo fT L R 2a g o n i s to r
water were added to 245 μl of serum-free medium. A
quantity of 100 μl of serum-free medium, TLR2 agonist
dilution or water dilution was added to a well of a 96-well
plate, with each condition represented in duplicate wells.
Aq u a n t i t yo f1 0 0μlo fp u r i f i e dh u m a nm o n o c y t e sa ta
concentration of 5 × 10
5 cells/ml in serum-free medium
was then added to each well. Fibrocytes were fixed, stained
and counted after monocytes were cultured for 5 days.
Treating monocytes with conditioned media from PBMC
stimulated with TLR2 agonists
To make conditioned medium, a dilution of TLR2 ago-
nists was made as described above. A quantity of 100 μl
of either SFM, the TLR2 agonist dilution or the corre-
sponding water dilution was added to duplicate wells of
a 96-well plate along with 100 μl of PBMCs at a concen-
tration of 5 × 10
5 cells/ml in SFM. After 3 days of incu-
bation, 180 μl of the conditioned media from one well
representing each condition were transferred into an
Eppendorf tube, snap-frozen in liquid nitrogen and
stored at -20°C. For the well from which the medium
was not removed, at day 5 the fibrocytes were fixed,
stained and counted as previously described [5-7]. Also
on day 5, monocytes were prepared from the same
donor as described above. A quantity of 50 μlo f
monocytes at a concentration of 1 × 10
6 cells/ml was
incubated with 50 μl of the day 3 conditioned medium.
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number of fibrocytes was counted.
Detection of cytokines and SAP by enzyme-linked
immunosorbent assay
The day 3 conditioned media were analyzed for IFN-a,
IFN-g and IL-12 using enzyme-linked immunosorbent
assay (ELISA) according to the manufacturer’si n s t r u c -
tions (Peprotech, Rocky Hill, NJ, USA). The day 3 con-
ditioned media were also analyzed for IL-2, IL-4, IL-5,
IL-6, IL-10, IL-12, IL-13, IL-17A, IFN-g,T N F - a, granu-
locyte colony-stimulating factor (G-CSF) and tumor
growth factor (TGF)-b1 using a multi-analyte profiler
ELISArray kit according to the manufacturer’si n s t r u c -
tions (SABiosciences, Frederick, MD, USA).
The day 3 conditioned media were also analyzed for
SAP as described previously [5,27], with the exception
that the ELISA plates were coated overnight at 4°C with
mouse antihuman SAP antibody (SAP-5; Sigma, St.
Louis, MO, USA) diluted 1:1,000 in phosphate-buffered
saline (PBS) instead of 50 mM sodium carbonate buffer,
and undiluted day 3 conditioned media were assayed.
Staining PBMC with CD86 or MHC Class II
Human PBMCs were cultured in the presence or absence
of 8.9 μg/mL TLR3 agonist Poly (I:C), 0.89 μg/mL TLR7
agonist imiquimod (IMIQ), or 2.0 μg/ml nucleotide oligo-
merization domain (NOD)-like receptor (NLR) agonist
peptidoglycan (PGN) in 1 ml in the well of a 48-well plate.
On day 1 or 3, 900 μl of the conditioned media were care-
fully pipetted out and transferred into an Eppendorf tube,
snap-frozen in liquid nitrogen and stored at -20°C. A quan-
tity of 500 μl of ice-cold 50 mM ethylenediaminetetraacetic
acid (EDTA) in PBS was then added to the PBMCs for 5
minutes at 4°C. The cells were vigorously resuspended
with a plastic transfer pipette. The cells were transferred
into an Eppendorf tube, collected by centrifugation at 300
× g for 5 min and the supernatant was discarded. The
remaining cells on the plates were washed with 1 ml of ice-
cold PBS, and this solution was added to the first pellet of
cells. The cells were again collected by centrifugation at
300 × g for 5 min and then resuspended in 200 μlo f4 %
bovine serum albumin (BSA) in PBS. Cells treated with
TLR agonists were divided into two separate Eppendorf
tubes. The cells were incubated with 5 μg/ml antihuman
CD86 or 5 μg/ml antihuman Human leukocyte antigen-
DR/DP/DQ (HLA-DR/DP/DQ) (MHC class II) (both from
BD Biosciences) for 30 min at 4°C as described previously
[28]. Meanwhile, untreated cells were divided into three
separate Eppendorf tubes. These cells were incubated with
5 μg/ml antihuman CD86 or 5 μg/ml antihuman HLA-
DR/DP/DQ, or they were kept in 4% BSA in PBS for 30
min at 4°C. All of the cells were washed three times in 1
ml of ice-cold PBS and then incubated with 2.5 μg/ml goat
antimouse FITC (Southern Biotechnology, Birmingham,
AL, USA) for 30 min at 4°C as described previously [28].
After washing the cells three times in 1 ml of ice-cold PBS,
the cells were resuspended in 100 μl of 4% BSA-PBS, and
the staining was analyzed using flow cytometry with an
Accuri C6 cytometer (Accuri Cytometers Inc.).
Detection of Ig molecules by Western blot analysis
Human IgG (Jackson ImmunoResearch Laboratories,
West Grove, PA, USA) was diluted to 10 μg/ml, 1 μg/ml
and 0.1 μg/ml in PBS. A quantity of 10 μl of conditioned
media from day 3 or diluted human IgG was mixed with
2.5 μl of sodium dodecyl sulfate (SDS) sample buffer con-
taining 20 mM dithiothreitol (DTT) and heated to 100°C
for 5 min. After electrophoresis of the samples on 4-15%
Tris-glycine polyacrylamide gels (Bio-Rad Laboratories,
Hercules, CA, USA), proteins were transferred to polyvi-
nylidene difluoride (PVDF) membranes (Millipore, Bed-
ford, MA, USA) in Tris-NaCl-SDS buffer containing 20%
methanol. Western blot staining was performed as
described previously [5], with the exception that the detec-
tion antibody was 0.05 μg/ml biotinylated goat Fab’(2)
antihuman Ig (H+L) (Southern Biotechnology) followed by
1:5,000 ExtrAvidin-Peroxidase staining (Sigma).
Treating monocytes with different combinations of
cytokines
After analyzing the day 3 conditioned media with multi-
analyte ELISArray kits, we calculated the concentrations
of IL-6, IFN-g,T N F - a,G - C S F ,a n dT G F - b1i nL T A
(TLR2 agonist)-treated conditioned media, LPS (TLR4
agonist)-treated conditioned media and control condi-
tioned media. Cocktails of cytokines corresponding to
twice the observed concentrations were made in SFM. A
quantity of 100 μl of purified human monocytes at a
concentration of 5 × 10
5 cells/ml were incubated in 100
μl of SFM, 100 μl of the above cytokine cocktails or 100
μlo ft h ec y t o k i n ec o c k t a i lw i t ha l lf i v eo ft h ea b o v e
cytokines at either 2,000 pg/ml, 1,000 pg/ml, 200 pg/ml
or 20 pg/ml. After 5 days, cells were fixed and stained,
and fibrocytes were counted.
Statistics
Statistical analysis was performed using GraphPad Prism
software (GraphPad Software, San Diego, CA, USA).
Statistical significance was determined using either ana-
lysis of variance (ANOVA) or a t-test, and significance
was defined as P < 0.05.
Results
TLR3, TLR4, TLR5, TLR7, TLR8 and TLR9 agonists do not
inhibit the differentiation of PBMCs to fibrocytes
To investigate the role of TLR agonists on fibrocyte dif-
ferentiation, human PBMCs were cultured in the
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can affect each other, we used PBMCs instead of puri-
fied monocytes to more closely mimic a human immune
system. All of the TLR agonists were reconstituted in
endotoxin-free water, and a control series of water dilu-
tions had no discernible effect on fibrocyte differentia-
tion (data not shown).
All TLR agonists were used in dose ranges that had
induced responses in previous studies (Table 1). TLR3,
TLR7, TLR8 and TLR9 agonists consisted of viral, bac-
terial or synthetic nucleic acids that stimulated their
corresponding receptors. When added to PBMCs, none
of these agonists showed any significant effect on fibro-
cyte differentiation (Figures 1 and 2). The TLR9 agonist
Escherichia coli ssDNA appears to decrease fibrocyte
differentiation at 10 μg/ml (Figure 2B), but it was not
significant by either ANOVA or t-test. One batch of the
TLR7 agonist IMIQ inhibited fibrocyte differentiation at
3.3 μg/ml, but other batches of IMIQ from the same
manufacturer had no significant effect on fibrocyte dif-
ferentiation. Although TLR3, TLR7, TLR8 and TLR9
agonists do not affect fibrocyte differentiation, the TLR8
agonist ssRNA and the TLR9 agonist ODN2006 that we
used for these studies induced extracellular TNF-a
accumulation by PBMCs (Figure 3A). TLR3 and TLR7
agonists do not significantly enhance the production of
TNF-a, but the TLR3 agonist Poly (I:C) significantly
increased the number of CD86-positive cells at day 1
(Figure 3B) and the TLR7 agonist IMIQ significantly
increased the number of HLA-DR/P/Q (MHC class II)-
positive cells at day 3 (Figure 3C), which suggest that
these agonists still have biological effects on PBMCs.
TLR4 recognizes bacterial LPSs, and TLR5 recognizes
bacterial flagellin [29-31]. We observed that 0.89 μg/ml
LPS or 0.89 μg/ml flagellin had no effect on fibrocyte
differentiation (Figure 4). Although the number of fibro-
cytes decreased in PBMCs treated with LPS or flagellin,
t-tests showed no significant difference compared to no
TLR agonist. Both LPS and flagellin caused PBMCs to
increase their accumulation of extracellular TNF-a
(Figure 3A), which suggests that the LPS and flagellin
we used have biological effects on PBMCs. Together,
Table 1 TLR agonists stimulate different cytokines and effectors in various cell types
a
Agonist TLR Concentration
used
Cell type Effect References
Pam3CSK4 (synthetic) TLR2 0.30 μg/ml PBMC Induction of IL-6 [38]
Lipomannan M. smegmatis (LM-MS) TLR2 10 μg/ml PBMC Cellular aggregation [48]
Heat-killed Listeria monocytogenes
(HKLM)
TLR2 3 × 10
7 cells/ml PBMC Induction of type I and type II IFN [49]
Lipotechoic acid from S. aureus
(LTA)
TLR2 10 μg/ml RAW264.7 Increased expression of IL-1b, TNF-a, IL-6,
and IP-10
[50]
Lipopolysaccharide from P.
gingivalis (PG-LPS)
TLR2 0.1 μg/ml U373 Secretion of IL-6 [51]
FSL-1
(synthetic)
TLR2 0.1 μg/ml PBMC Induction of Type I and Type II IFN [49]
Poly (I:C) (synthetic) TLR3 10 μg/ml PBMC Production of IL-8, MCP-1, and TNF-a [52]
E. coli K12 lipopolysaccharide (LPS) TLR4 0.01, 0.1, and 1
μg/ml
PBMC Production of TNF-a, IL-6, and IL-10 [30,31]
S. typhimurium flagellin TLR5 0.1 μg/ml PBMC Activation of NF-B [29]
Imiquimod (IMIQ)
(synthetic)
TLR7 3 μg/ml PBMC Expression of IFN, TNF-a, IL-6, and IL-8
increased
[53]
Gardiquimod (GIMIQ)
(synthetic)
TLR7 1 μg/ml Plasmacytoid dendritic cells Expression of IFN-a, IFN-b, and RANTES
increased
[54]
Loxoribine
(synthetic)
TLR7 0.2 mM RAW264.7 mouse
macrophage cell line
NK cells
Expression of IL-23 p19 increased
Activation of NK cells
[55,56]
ssRNA40
(synthetic)
TLR8 1 μg/ml Peripheral blood Activation of TNF-a [57]
E. coli ssDNA/LyoVec TLR9 0.3-10 μg/ml RAW264.7 Production of nitrite [58]
ODN2006
(synthetic)
TLR9 2 μM PBMC Increased production of IFN-g, IFN-a, IL-6,
IL-8, and IL-12
[59,60]
ODN2216
(synthetic)
TLR-
9
1 μM Plasmacytoid dendritic
cells
Decreased production of IFN-a [61]
Peptidoglycan from S. aureus (PGN) NLR 0.1-10 μg/ml HEK-293 Activation of NF-B [62]
aThis table summarizes the concentration of agonists used by other workers. TLR, Toll-like receptor; PBMC, human peripheral blood mononuclear cells; IL,
interleukin; IFN, interferon; TNF, tumor necrosis factor; NF-B, nuclear factor-B; HEK-293, human embryonic kidney-293 cells; PGN, peptidoglycan.
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and TLR9 agonists do not significantly affect the in vitro
differentiation of human fibrocytes.
TLR2 agonists inhibit the differentiation of PBMCs to
fibrocytes
TLR2 receptors recognize bacterial lipoproteins and
lipotechoic acid from bacterial membranes, and they
mediate the activation of transcription factors such as
NF-B and IFN-regulatory factors [19,32-34]. We found
that at concentrations similar to those used in other stu-
dies (Table 1), all six TLR2 agonists tested inhibited
fibrocyte differentiation (Figure 5). At day 5, the TLR2
agonist-treated cells appeared to be viable as determined
by phase contrast microscopy (Figure 6). At day 5 after
T L R 2a g o n i s tt r e a t m e n t ,t h e r ew a sn os i g n i f i c a n t
difference in the number of viable PBMCs treated with
or without TLR2 agonists (Figure 6B).
Besides TLRs, there are also other pattern recognition
receptors (PRRs) present in PBMCs that detect a variety of
microbial molecules, including NLRs, that contain a NOD-
and ligand-recognizing leucine-rich repeat [35]. NLRs are
intracellular receptors that recognize a variety of microbial
molecules. We investigated the role of PGN on fibrocyte
differentiation, since this agonist appears to be a NLR ago-
nist [36]. When added to PBMCs, PGN at concentrations
from 0.01 to 6.7 μg/ml did not affect fibrocyte differentia-
tion (Figure 7). Although not statistically significant, PGN
increased the number of CD86- and MHC class II-positive
cells (Figures 3B and 3C). Together, the data suggest that
although PGN has no effect on fibrocyte differentiation
when added to PBMCs, it still has some effect on cells.
Figure 1 Toll-like receptor 3 (TLR3) and TLR7 agonists do not affect fibrocyte differentiation. Human peripheral blood mononuclear cells
(PBMCs) were cultured in different concentrations of the TLR3 agonist polyinosine-polycytidylic acid (Poly I:C) and the TLR7 agonists imiquimod
(IMIQ), gardiquimod (GIMIQ) and loxoribine. After 5 days, the cells were air-dried, fixed and stained, and the number of fibrocytes was counted.
The results are means ± SEM of fibrocytes per 2.5 × 10
5 PBMCs (n = 3 separate experiments). Although high concentrations of IMIQ and GIMIQ
appear to decrease the number of fibrocytes compared to no addition, the decrease is not significant by either analysis of variance (ANOVA) or
t-test. Arrows indicate the reported concentrations for the TLR agonists previously shown to be functional (Table 1).
Maharjan et al. Fibrogenesis & Tissue Repair 2010, 3:23
http://www.fibrogenesis.com/content/3/1/23
Page 5 of 13Some TLR2 agonists inhibit fibrocyte differentiation
indirectly
To determine whether TLR2 agonists act directly on
human monocytes, we examined the effect of TLR2 ago-
nists on purified monocytes. When TLR2 agonists were
added to purified human monocytes, the TLR2 agonists
did not inhibit the differentiation of monocytes to fibro-
c y t e s( F i g u r e8 ) .T h i ss u g g e s t st h a tT L R 2a g o n i s t sd o
not inhibit fibrocyte differentiation by acting directly on
monocytes. Interestingly, the NLR agonist PGN poten-
tiated the differentiation of monocytes to fibrocytes
(Figure 8). Since PGN had little activity when added to
PBMCs (Figure 7), PGN might act directly on mono-
cytes to potentiate fibrocyte differentiation and this
activity might be inhibited by the presence of the other
cells in the PBMC population. TLR4 agonist LPS also
potentiated the differentiation of monocytes to fibro-
cytes (Figure 8), though the increase was not significant
by either ANOVA or t-test.
Since TLR2 agonists do not act directly on monocytes,
a possible explanation for the ability of TLR2 agonists
to inhibit fibrocyte differentiation when added to
PBMCs is that the TLR2 agonists cause some cells in
the PBMC population, such as T, B or NK cells, to
secrete a factor that inhibits the differentiation of mono-
cytes to fibrocytes. To test this possibility, we incubated
PBMCs for 3 days with TLR2 agonists, collected the
conditioned media and then added this to monocytes
from the same donor. As previously observed, when
added to PBMCs, TLR2 agonists inhibited the differen-
tiation of fibrocytes (Figure 9A). Conditioned media
from PBMCs incubated with the TLR2 agonists lipo-
mannans from Mycobacterium smegmatis (LM-MS),
LPSs from Porphyromonas gingivalis (PG-LPS) and LTA
for 3 days inhibited the differentiation of monocytes to
fibrocytes (Figure 9B). This suggests that these TLR2
agonists cause some nonmonocyte cells in the PBMC
population to increase the accumulation of fibrocyte-
inhibiting factors or to decrease the accumulation of
fibrocyte-promoting factors in the extracellular medium.
Some TLR2 agonists cause PBMCs to secrete an unknown
factor that inhibits fibrocyte differentiation
We previously found that 1 ng/ml or more IFN-g,
0.5 μg/ml or more SAP or 10 μg/ml or more aggregated
IgG directly inhibits monocytes from differentiating into
Figure 2 TLR8 and TLR9 agonists do not affect fibrocyte differentiation. Human PBMCs were cultured in different concentrations of the
TLR8 agonist single-stranded RNA40 (ssRNA40) and the TLR9 agonists Escherichia coli ssDNA, ODN2006 and ODN2216. ODN2006 and ODN2216
are synthetic oligonucleotides that contain CpG dinucleotides at specific sequences. The controls for these oligonucleotides are ODN2006
control and ODN2216 control, which contain GpC dinucleotides instead of CpG dinucleotides. After 5 days, the cells were air-dried, fixed and
stained, and the number of fibrocytes was counted. The results are means ± SEM of fibrocytes per 2.5 × 10
5 PBMCs (n = 3 separate
experiments). Although high concentrations of E. coli ssDNA appear to decrease the number of fibrocytes compared to no addition, the
decrease is not significant by either ANOVA or t-test. High concentrations of ODN2216 and ODN2216 control appear to increase fibrocyte
number compared to no addition, but the increase is not significant by either ANOVA or t-test. Arrows indicate the concentrations of TLR
agonists used by other workers (Table 1).
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bits fibrocyte differentiation [5-7]. In cultures of PBMCs
containing fetal bovine serum, IFN-a inhibits fibrocyte
differentiation [13]. In our serum-free culture system, 0.1
ng/ml or more IFN-a also inhibited fibrocyte differentia-
tion (Figure 10). To determine whether one of these inhi-
bitory factors is the antifibrocyte factor present in
conditioned media from PBMCs incubated with the
TLR2 agonists LM-MS, PG-LPS and LTA, we examined
the levels of IFN-a,I F N - g, IL-12, SAP and IgG in the
conditioned media. Conditioned media from PBMCs
incubated with TLR2 agonists as well as the TLR4
agonist LPS did not show any detectable levels of IL-12
or SAP, with a detection limit of 0.1 ng/ml for both fac-
tors (data not shown). These conditioned media also had
less than 0.01 ng/ml IFN-g (Table 2 and data not shown).
The conditioned media also did not show any detectable
levels of either IFN-a or IgG, with a detection limit of 1
pg/ml IFN-a and 1 μg/ml IgG (data not shown). We
further analyzed day 3 conditioned media from PBMCs
incubated with Pam3CSK4, PG-LPS, LTA, PGN and LPS
for the presence of Th1/Th2/Th17 cytokines. There were
no detectable levels of IL-2, IL-4, IL-5, IL-10, IL-12, IL-
13 or IL-17A with a detection level of approximately 15
Figure 3 TLR agonists affect PBMCs. (A). Human PBMCs were cultured in the absence (serum-free medium (SFM) control) or the presence of
0.89 μg/ml TLR2 agonists Pam3CSK4, 8.9 × 10
7 cells/ml heat-killed Listeria monocytogenes (HKLM), 1.79 μg/ml lipotechoic acid (LTA), or 8.9 μg/ml
lipopolysaccharides from Porphyromonas gingivalis (PG-LPS), 8.9 μg/ml TLR3 agonist Poly (I:C), 0.89 μg/ml TLR4 agonist LPS, 0.89 μg/ml TLR5
agonist flagellin, 0.89 μg/ml TLR2/6 agonist FSL-1, 0.89 μg/ml TLR7 agonist IMIQ, 0.89 μg/ml TLR8 agonist ssRNA, 4.47 μM TLR9 agonist ODN
2006 or 1.79 μg/ml nucleotide oligomerization domain (NOD)-like receptor (NLR) agonist peptidoglycan (PGN). On day 3, the conditioned media
were tested for the presence of tumor necrosis factor (TNF)-a using enzyme-linked immunosorbent assay. The results are means ± SEM of TNF-a
concentration (n = 3 or more separate experiments). (B) Human PBMCs were cultured in the presence or absence of Poly (I:C), IMIQ and PGN as
described for Figure 3A. After 1 day, PBMCs were removed and stained for CD86 (n = 3 separate experiments). (C) Human PBMCs were cultured
in the presence or absence of 8.9 μg/ml TLR3 agonist Poly (I:C), 0.89 μg/ml TLR7 agonist IMIQ or 1.79 μg/ml NLR agonist PGN. On day 3, PBMCs
were removed from the tissue culture plate and stained for major histocompatibility complex (MHC) class II. The results are means ± SEM of
positive MHC class II cells (n = 4 separate experiments). *P < 0.05 and **P < 0.01 compared to no-agonist control (SFM) according to t-test.
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TNF-a, IFN-g, G-CSF and TGF-b1 in conditioned media
from LTA (TLR2 agonist)-treated PBMCs, LPS (TLR4
agonist)-treated PBMCs, and control PBMCs (Table 2).
We then analyzed the effect of cocktails of these five
cytokines on fibrocyte differentiation. Cytokine cocktails
corresponding to the amount of the five cytokines found
in LTA-treated conditioned media, LPS-treated condi-
tioned media or control conditioned media did not have
any significant effect on fibrocyte differentiation (Figure
11). In addition, cocktails containing higher levels of the
five cytokines had no significant effect on fibrocyte differ-
entiation (Figure 11). These observations indicate that
the LTA-induced factor in the PBMC conditioned media
that inhibits fibrocyte differentiation is not one of the five
cytokines that we found in LTA-treated conditioned
media and thus appears to be a novel factor.
Discussion
We found that a variety of TLR2 agonists inhibit fibro-
cyte differentiation. However, the TLR2 agonists do not
Figure 4 TLR4 and TLR5 agonists do not affect fibrocyte
differentiation. Human PBMCs were cultured in the presence or
absence of 0.89 μg/ml TLR4 agonist LPS or 0.89 μg/ml TLR5 agonist
flagellin. After 5 days, the cells were air-dried, fixed and stained, and
the number of fibrocytes was counted. The results are means ±
SEM of fibrocytes per 2.5 × 10
5 PBMCs (n = 6 separate experiments).
Although LPS and flagellin appear to decrease the number of
fibrocytes compared to no addition, the decrease is not significant
by either ANOVA or t-test.
Figure 5 TLR2 agonists inhibit fibrocyte differentiation. Human PBMCs were cultured in different concentrations of the TLR2 agonists
Pam3CSK4, HKLM, lipomannans from Mycobacterium smegmatis (LM-MS), LTA, PG-LPS and FSL-1. After 5 days, the cells were air-dried, fixed and
stained, and the number of fibrocytes was counted. The results are means ± SEM of fibrocytes per 2.5 × 10
5 PBMCs (n = 6 separate experiments
for Pam3CSK4 and n = 3 separate experiments for the rest of the TLR2 agonists). The absence of error bars indicates that the error was smaller
than the plot symbol. Statistical significance was analyzed by ANOVA using Dunnett’s test to compare values against the no-agonist control for
all the agonists except LM-MS, which was analyzed by t-test. *P < 0.05, **P < 0.01, and ***P < 0.001 compared to no-agonist control. Arrows
indicate the concentration of TLR2 agonists used by other workers (Table 1).
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Page 8 of 13directly inhibit the differentiation of monocytes to
fibrocytes, but rather cause some other cell type in the
PBMC population to inhibit monocytes from differen-
tiating into fibrocytes. There are five known factors
(IFN-a,I F N - g, IL-12, SAP and aggregated IgG) which
inhibit fibrocyte differentiation [5-7,13]. Our data sug-
gest that PBMCs incubated with some TLR2 agonists
secrete an unknown sixth factor that inhibits fibrocyte
differentiation.
The TLR2 agonist LTA induces PBMCs to increase the
extracellular accumulation of IL-6, TNF-a,I F N - g and G-
CSF and to decrease the extracellular accumulation of
TGF-b1. Both TLR2 agonists and TLR4 agonist induce
primary adrenocortical cells to secrete IL-6 [37,38]. How-
ever, we previously found that IL-6 has no effect on
fibrocyte differentiation [7]. Like the above five factors,
this combination of cytokines at the concentrations
found in the conditioned media, or at higher concentra-
tions, was unable to inhibit fibrocyte differentiation and
is thus not the factor in LTA-stimulated conditioned
medium that inhibits fibrocyte differentiation.
Monocytes express TLR1-TLR9, but not TLR10
[39,40]. They have a high expression of TLR1, TLR2
and TLR4; intermediate expression of TLR 5, TLR6 and
TLR8; and low expression of TLR7 and TLR9 [39,40].
Once activated, TLR agonists trigger downstream signal-
ing events by one of four adaptor molecules: MyD88,
MyD88-like adaptor protein (Mal), Toll/Interleukin-1
receptor (TIR) domain-containing adaptor protein-indu-
cing IFN-b (TRIF) or TRIF-related adaptor molecule
(TRAM) [41-45]. MyD88 activates mitogen-activated
protein kinases (MAPKs) through IL-1R-associated
kinase (IRAK) and tumor necrosis factor receptor
(TNFR)-associated factor 6 (TRAF-6) [41,45]. The sig-
naling eventually causes the translocation of transcrip-
tion factors such as NF-B and activator protein 1 (AP-
1), which then induces the production of inflammatory
c y t o k i n e ss u c ha sT N F - a,I L - 6 ,I L - 1 b and IL-12 [41].
TLR3 does not require the MyD88 pathway; instead it
induces the production of IFN-b via TRIF [41,46]. TLR4
can cause NF-B activation by either a MyD88-depen-
dent pathway or a MyD88-independent pathway [42].
Figure 6 Human PBMCs cultured in the presence of TLR2 agonists are viable.H u m a nP B M C sw e r ec u l t u r e di nt h e(A).a b s e n c eo r(B)
presence of 1.79 μg/ml TLR2 agonist LTA or (C) 0.89 μg/ml TLR7 agonist IMIQ. After 5 days, the cells cultured in different conditions were
photographed. Bar is 20 μm. (D) Human PBMCs were cultured in the absence (SFM control) or presence of 0.89 μg/ml TLR2 agonists Pam3CSK4,
8.9 × 10
7 cells/ml HKLM, 0.89 μg/ml LM-MS, 1.79 μg/ml LTA, 8.9 μg/ml PG-LPS or 0.89 μg/ml FSL-1 for 5 days. After 5 days, the cells were
photographed and the number of cells per picture was counted. The results are means ± SEM of cells per 0.15 mm
2 (n = 3 separate
experiments).
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Page 9 of 13TLR4 activates a MyD88-independent pathway via TRIF,
which complexes with TRAM and leads to NF-Ba c t i -
vation [42]. Since none of the TLR agonists appeared to
directly inhibit the differentiation of monocytes to fibro-
cytes, our data suggest that none of the above signal
transduction pathways in monocytes affects their ability
to differentiate into fibrocytes.
TLR2 recognizes various bacterial components such
as bacterial lipoproteins and LTA [41,47]. PBMCs
incubated with the TLR2 agonists LM-MS, PG-LPS
and LTA secrete an unknown factor that inhibits fibro-
cyte differentiation. However, for unknown reasons,
the TLR2 agonists Pam3CSK4 (a synthetic triacylated
lipopeptide), heat-killed Listeria monocytogenes
Figure 8 TLR2 agonists do not inhibit the differentiation of
purified monocytes to fibrocytes. Human monocytes were
cultured in SFM for 5 days in the presence of LPS (1 μg/ml), PGN (2
μg/ml), Pam3CSK4 (1 μg/ml), HKLM (1 × 10
8 cells/ml), LM-MS (1 μg/
ml), PG-LPS (10 μg/ml), LTA (2 μg/ml) and FSL-1 (1 μg/ml). The
results are means ± SEM of fibrocytes per 2.5 × 10
5 PBMCs (n = 4
separate experiments). *P < 0.05 compared to control (one-way
ANOVA, Dunnett’s test).
Figure 9 Conditioned media from PBMCs incubated with LM-
MS, PG-LPS and LTA inhibit fibrocyte differentiation. (A).
Human PBMCs were cultured for 5 days in the presence of the TLR2
agonists Pam3CSK4, HKLM, LM-MS, PG-LPS, LTA and FSL-1, the TLR4
agonist LPS, and the NLR agonist PGN, using the same
concentrations as in Figure 6. SFM was used as a buffer control, and
LPS and PGN were used as negative controls, since these agonists
do not inhibit fibrocyte differentiation. Conditioned media were
removed on day 3 from duplicates of these wells. The results are
means ± SEM of fibrocytes per 2.5 × 10
5 PBMCs (n = 5 separate
experiments). *P < 0.05, **P < 0.01, and ***P < 0.001 compared to
control (one-way ANOVA, Dunnett’s test). (B) Human monocytes
were cultured for 5 days in the presence of the conditioned media
from day 3 PBMCs incubated with TLR2 agonists. The results are
means ± SEM of fibrocytes per 2.5 × 10
5 PBMCs (n = 5 separate
experiments). Conditioned media from PBMCs incubated with the
TLR2 agonists LM-MS, PG-LPS and LTA significantly inhibited the
differentiation of monocytes to fibrocytes. *P < 0.05 compared to
control (one-way ANOVA, Dunnett’s test).
Figure 10 Interferon (IFN)-a inhibits fibrocyte differentiation.
Human PBMCs were cultured in different concentrations of IFN-a.
After 5 days, the cells were air-dried, fixed and stained, and the
number of fibrocytes was counted. The results are means ± SEM of
fibrocytes per 2.5 × 10
5 PBMCs (n = 3 separate experiments). *P <
0.05 and **P < 0.01 compared to no IFN-a control (one-way
ANOVA, Dunnett’s test).
Figure 7 The NLR agonist PGN does not affect fibrocyte
differentiation. Human PBMCs were cultured in different
concentrations of PGN. After 5 days, the cells were air-dried, fixed
and stained, and the number of fibrocytes was counted. The results
are means ± SEM of fibrocytes per 2.5 × 10
5 PBMCs (n = 3 separate
experiments). There was no statistically significant difference
between the effect of any PGN concentration and control,
according to ANOVA or t-test. Arrows indicate the concentrations of
PGN used by other workers (Table 1).
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Page 10 of 13(HKLM) and FSL-1 (a synthetic lipoprotein) do not
appear to cause other cells in the PBMC population to
secrete factors that inhibit fibrocyte differentiation.
This suggests that these agonists indirectly inhibit
fibrocyte differentiation by either cell-cell contact or a
labile secreted factor.
W ep r e v i o u s l yf o u n dt h a ta g g r e g a t e dI g Gi n h i b i t s
fibrocyte differentiation [6]. We hypothesized that since
aggregated IgG (that is, IgG bound to something such
as a bacterium) signifies the presence of bacterial infec-
tion, and since closing an infected wound and thus
forming an anaerobic pocket can be detrimental, the
inhibition of fibrocyte differentiation by aggregated IgG
might have evolved to prevent closure of septic wounds
by fibrocytes. An interesting possibility is that the
indirect inhibition of fibrocyte differentiation by TLR2
agonists allows other cells in a wound environment to
check for the presence of bacteria, and if bacteria are
present, to relay this information to monocytes and pre-
vent fibrocyte differentiation and the possible closure of
an infected wound.
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